New model could benefit liver cancer transplant patients

December 21, 2016 by Jamie Black

A simple blood test may better predict which patients diagnosed with liver cancer will experience disease recurrence, according to new research from Weill Cornell Medicine scientists. The findings may help physicians determine who would benefit most from a liver transplant.

Depending on disease severity, oncologists may recommend for patients whose tumors have not yet metastasized. Physicians have traditionally used a special set of criteria, based on the size and number of tumors, to assess patients' risk of cancer reoccurrence if they receive a new organ – the findings from which ultimately determine if transplantation is the appropriate treatment.

In their study, published Sept. 16 in the Annals of Surgery, Weill Cornell Medicine investigators demonstrate that measuring the concentration of molecules in the blood that increase in the presence of can discern which patients will experience disease relapse more effectively than the current model. The scientists say the new criteria, known as the Model of Recurrence After Liver Transplant – or MORAL score – can help ensure that those who are selected for have the best chance of staying cancer-free after surgery.

"At the end of the day, our goal is to use better predictors to provide patients with improved treatment options," said Dr. Robert Brown, the Gladys and Roland Harriman Professor of Medicine at Weill Cornell Medicine and co-creator of the MORAL criteria. "By using pre-transplant biomarkers focused more on the growth and aggressiveness of liver cancer, we can determine which patients will do better with a liver transplant and which patients would benefit from more aggressive pre-transplant therapies to control their cancer."

In conjunction with surgeon Dr. Karim Halazun, an assistant professor of surgery at Weill Cornell Medicine, and other surgeons from NewYork-Presbyterian, Brown prospectively studied a cohort of 339 patients with hepatocellular carcinoma who had undergone transplantation to determine whether the MORAL criteria, compared with the traditional Milan criteria, could better predict cancer recurrence. Measuring common blood tests – including the breakdown of the white blood cells, specifically the neutrophil and lymphocytes, and the amount of a tumor marker protein, the alpha-fetoprotein, in the blood – correctly predicted 91 percent of the time, while the Milan criteria only yielded a 63 percent accuracy rate, Brown said.

"Using our MORAL score, we want to help patients lead longer lives," said Brown, director of the Center for Liver Disease and Transplantation and a hepatologist at NewYork-Presbyterian Weill Cornell Medical Center. "By combining this score with therapies we are developing to selectively change immune suppression in high-risk patients, we would be able to tell the risk of their cancer returning and at the same time tell them we have a plan for reducing that risk – that we can do something about it."

Explore further: Researchers develop more accurate tool to predict whether liver cancer will recur in transplant patients

Related Stories

Researchers develop more accurate tool to predict whether liver cancer will recur in transplant patients

March 13, 2015
UCLA transplant researchers have developed a novel method to more accurately calculate the risk of disease recurring in people with liver cancer who have undergone a liver transplant. The approach gives physicians a new tool ...

Team develops new tool to predict postoperative liver cancer recurrence after transplant

January 13, 2015
UCLA transplantation researchers have developed a novel method that more accurately calculates the risk of disease recurrence in liver cancer patients who have undergone a liver transplant, providing a new tool to help physicians ...

Freezing technique is an effective alternative to lumpectomy for early stage breast cancer

September 27, 2016
A deep-freezing technique known as cryoablation is a viable alternative to traditional surgery in many early-stage breast cancers, NewYork-Presbyterian and Weill Cornell Medicine researchers find in a new clinical study. ...

HIV no barrier to getting liver transplant, study finds

May 17, 2013
(HealthDay)—Liver transplants to treat a common type of liver cancer are a viable option for people infected with HIV, according to new research.

Fatty liver disease is common

April 11, 2016
Researchers have characterized the prevalence and risk factors of fatty liver disease in patients who undergo liver transplantation. The findings, which are published in Liver Transplantation, a journal of the American Association ...

Recommended for you

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.